Supriya Lifescience Limited (BOM:543434)

India · Delayed Price · Currency is INR

836.70

+8.05 (0.97%)

At close: Jul 20, 2026

17.61% (1Y)

Market Cap	67.39B +17.7%
Revenue (ttm)	8.28B +18.9%
Net Income	2.09B +11.3%
EPS	25.98 +11.3%
Shares Out	n/a
PE Ratio	32.22
Forward PE	n/a
Dividend	1.00 (0.12%)
Ex-Dividend Date	Sep 4, 2025

Volume	15,991
Open	824.40
Previous Close	828.65
Day's Range	824.40 - 846.60
52-Week Range	545.65 - 1,085.50
Beta	n/a
Analysts	Buy
Price Target	940.00 (+12.35%)
Earnings Date	Aug 10, 2026

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, ... [Read more]

Industry Pharmaceutical Preparations

Founded 1987

Employees 515

Stock Exchange Bombay Stock Exchange

Ticker Symbol 543434

Full Company Profile

Financial Performance

In fiscal year 2026, Supriya Lifescience's revenue was 8.28 billion, an increase of 18.86% compared to the previous year's 6.96 billion. Earnings were 2.09 billion, an increase of 11.26%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 543434 stock is "Buy." The 12-month stock price target is ₹940.00, which is an increase of 12.35% from the latest price.

Price Target

₹940.00

(12.35% upside)

Analyst Consensus: Buy

Stock Forecasts